---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-22-000044"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:07:25.229321+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sema4 Q1 2022: revenue $53.9M, net loss $76.9M; closes GeneDx acquisition, raises cash burn savings to $50M

## Summary
- Total revenue $53.9M (incl. COVID-19); ex-COVID revenue $50.1M, up 4% YoY.
- Adjusted gross margin 13%, up ~1,300 bps sequentially; net loss $76.9M, adjusted net loss $65.5M.
- Completed GeneDx acquisition in April; $200M private placement closed with Pfizer among investors.
- Reaffirms FY2022 pro forma revenue target $350M; total revenue guidance $305-315M.
- Cash $315M as of March 31; expects to reduce 2022 cash burn by $50M, extending runway into 2024.

## SEC filing metadata
- accession: 0001818331-22-000044
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/0001818331-22-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/smfr-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-22-000044
- JSON: https://secwatch.observer/filing/0001818331-22-000044.json
- Plain text: https://secwatch.observer/filing/0001818331-22-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.